

## Autologous Serum Tears

### Table of Content

- [Purpose](#)
- [Description & Definitions](#)
- [Criteria](#)
- [Coding](#)
- [Document History](#)
- [References](#)
- [Special Notes](#)
- [Keywords](#)

<u>Effective Date</u>	9/2007
<u>Next Review Date</u>	9/2024
<u>Coverage Policy</u>	Medical 244
<u>Version</u>	4

**All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member’s condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.**

### Purpose:

This policy addresses the medical necessity of - Autologous Serum Tears

### Description & Definitions:

Autologous serum tears use an individual’s own blood for the preparation and production of serum for dry eyes.

### Criteria:

Autologous Serum Tears are considered medically necessary for **ALL of the following**:

- Individual has Sjogrens disease.
- Individual has failed other treatments.

Autologous Serum Tears are considered not medically necessary for any use other than those indicated in clinical criteria.

### Coding:

Medically necessary with criteria:

Coding	Description
92499	Unlisted ophthalmological service or procedure.

Considered Not Medically Necessary:

Coding	Description
--------	-------------

	None
--	------

U.S. Food and Drug Administration (FDA) - approved only products only.

## Document History:

### Revised Dates:

- 2020: January
- 2015: March
- 2013: August
- 2012: August
- 2011: September
- 2010: December
- 2009: November

### Reviewed Dates:

- 2023: September
- 2022: September
- 2021: December
- 2020: December
- 2019: December
- 2018: October
- 2017: November
- 2016: August
- 2015: August
- 2014: August
- 2010: August, November
- 2009: August
- 2008: August

### Effective Date:

- September 2007

## References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved Aug 30, 2023, from Hayes, Inc:

<https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522autologous%2520Serum%2520Tears%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%2527B%2522page%2522:0,%2522size%2522:50%2527D,%2522type%2522:%2522all%2522,%252>

(2023). Retrieved Aug 30, 2023, from Centers for Medicare and Medicaid Services:

<https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Tears&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance>

(2023). Retrieved Aug 30, 2023, from Carelon Medical Benefits Management:

[https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Autologous+serum+tears&et\\_pb\\_searchform\\_submit=et\\_search\\_proccess&et\\_pb\\_search\\_cat=11%2C1%2C96&et\\_pb\\_include\\_posts=yes](https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Autologous+serum+tears&et_pb_searchform_submit=et_search_proccess&et_pb_search_cat=11%2C1%2C96&et_pb_include_posts=yes)

(2023, Jun 27). Retrieved Aug 30, 2023, from MCG: <https://careweb.careguidelines.com/ed27/index.html>

(2023). Retrieved Aug 30, 2023, from Department of Medical Assistance Services: <https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-library#gsc.tab=0&gsc.q=autologous%20serum%20tears&gsc.sort=>

Autologous Serum-Based Eye Drops for Treatment of Ocular Surface Disease OTA. (2019, Aug). Retrieved Aug 30, 2023, from American Academy of Ophthalmology: <https://www.aao.org/education/ophthalmic-technology-assessment/autologous-serum-based-eye-drops-treatment-of-ocul>

Baer, A., & Akpek, E. (2022, Mar 07). Treatment of moderate to severe dry eye in Sjögren's disease. Retrieved Aug 30, 2023, from UpToDate: [https://www.uptodate.com/contents/treatment-of-moderate-to-severe-dry-eye-in-sjogrens-disease?search=autologous%20serum%20tears%5D&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1#H1638685620](https://www.uptodate.com/contents/treatment-of-moderate-to-severe-dry-eye-in-sjogrens-disease?search=autologous%20serum%20tears%5D&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1638685620)

Bedinghaus, T. (2023, May 23). Will Autologous Serum Eye Drops Work for Me? Retrieved Aug 30, 2023, from Very Well Health: <https://www.verywellhealth.com/autologous-serum-eye-drops-3422030>

Guidance, Compliance & Regulatory Information (Biologics). (2022, Dec 14). Retrieved Aug 30, 2023, from U.S. Food and Drug Administration: <https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics>

### Special Notes: \*

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

### Keywords:

Autologous Serum Tears, SHP Prolotherapy, Medical 108, SHP Medical 244, Sjogren's Disease, dry eyes, Autologous serum eye drops, ASED, Biological tear substitute, Autologous serum, AS